Health care stocks were rising premarket Wednesday, with The Health Care Select Sector SPDR Fund (XLV) up 0.8% and the iShares Biotechnology ETF (IBB) 1.8% higher.
Keros Therapeutics (KROS) shares were down 25% after the company said it has voluntarily halted all dosing in its phase 2 TROPOS trial for cibotercept in patients with pulmonary arterial hypertension due to "new observations of pericardial effusion adverse events."
NeoGenomics (NEO) stock was over 6% higher after the company said it expects 2025 total revenues in the range of $735 million to $745 million. Analysts surveyed by FactSet expect $727.8 million.
Context Therapeutics (CNTX) shares were more than 10% higher after the company said it has dosed the first patient in the phase 1 study of CTIM-76, its lead drug candidate targeting Claudin 6-positive gynecologic and testicular cancers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.